Design Therapeutics, Inc.
Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027
Company newsroom
NASDAQ:DSGN
1 releases
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027